Clinicopathological Characteristics and Treatment Patterns of Extremity, Trunk, and Axial Sarcomas: A Descriptive Real-World Cohort Study from a Romanian Tertiary Oncology Center
Authors:
- Mihai-Teodor GeorgescuMGMihai-Teodor Georgescu
- Adelina Silvana GheorgheAdelina Silvana Gheorghe
- Romina-Marina SimaRSRomina-Marina Sima
- Bashar Haj HamoudBHBashar Haj Hamoud
- Georgia Luiza SerbanescuGSGeorgia Luiza Serbanescu
- Andreea Veronica LazescuALAndreea Veronica Lazescu
- Oana Gabriela TrifanescuOTOana Gabriela Trifanescu
- Radu Iulian MitricaRMRadu Iulian Mitrica
- Laurentia Nicoleta GalesLGLaurentia Nicoleta Gales
- Roxana Rahnea-NitaRRRoxana Rahnea-Nita
- Andra-Elena Balcangiu-StroescuABAndra-Elena Balcangiu-Stroescu
Open Access
- 28 May 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1659
Abstract
Background and Objectives: Sarcomas are rare malignancies of mesenchymal origin comprising less than 1% of all adult solid tumors, exhibiting marked histological heterogeneity and variable clinical behavior. Data from Eastern European tertiary oncology centers remain scarce. This study characterized the clinicopathological features, treatment modalities, and survival outcomes of patients with sarcomas of the extremities and trunk treated at the “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology from Bucharest over a ten-year period. Materials and Methods: We conducted a retrospective analysis of 164 patients diagnosed with sarcomas of the extremities and trunk between 2010 and 2020 at “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology. Variables included age, sex, tumor localization, histological subtype, immunohistochemical profile, treatment modalities, recurrence, metastatic spread, and overall survival (OS). Kaplan–Meier curves estimated survival; log-rank tests were applied for subgroup comparisons. Results: The cohort comprised 82 males and 82 females (50.0% each), with a mean age of 48.8 ± 18.3 years. The lower limb was the most frequent site (n = 96, 58.5%), particularly the thigh/femur (34.1%). The most common subtypes were undifferentiated pleomorphic sarcoma (14.6%), osteosarcoma (12.2%), and fibrosarcoma (11.0%). Surgery was performed in 75.6%, chemotherapy in 80.5%, and radiotherapy in 59.8%. Local recurrence occurred in 35.4% and distant metastases in 41.5%. The median OS was 96.0 months (vital status known for 160/164 patients; 90 deceased, 70 alive; OS duration available in 126 patients). Metastatic disease was associated with shorter observed survival in descriptive Kaplan–Meier analysis (log-rank p < 0.001); this comparison is exploratory given the time-dependent nature of the variable. Survival ranged from 11.5 months (leiomyosarcoma) to 162.5 months (dermatofibrosarcoma protuberans) by histotype. Conclusions: This study provides clinically relevant epidemiological and survival data from Romania. The findings illustrate real-world heterogeneity of sarcoma presentations and outcomes at an Eastern European tertiary center and highlight the need for improved diagnostic standardization, prospective data collection, and integration within specialized sarcoma networks.Keywords
Funding Information
- University of Medicine Pharmacy “Carol Davila”
This publication has 41 references indexed in Scilit:
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialThe Lancet, 2019
- Subclassification of pleomorphic sarcomas: How and why should we care?Annals of Diagnostic Pathology, 2018
- Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reportingEuropean Journal of Cancer, 2016
- Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and BoneCancer, 2014
- Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE projectEuropean Journal of Cancer, 2013
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trialThe Lancet, 2002
- Surgical margins, local recurrence and metastasis in soft tissue sarcomasEuropean Journal of Cancer, 2000
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997